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The reversal of congenital hypogonadotropic hypogonadism (CHH) 
is a relatively recent phenomenon that has gained increasing attention 
over the past 10  years. Yet to date, only one prospective study has 
been conducted estimating that 10% (95% confidence interval [CI]: 
2%–18%) of cases undergo reversal.1 Other retrospective studies 
have reported rates in the range of 5%–8%2,3 and a recent study 
showed 44/308 (14%, 95% CI: 11%–19%) CHH patients underwent 
reversal.4 Moreover, a time-to-event analysis in this large cohort 
revealed a lifetime reversal incidence of 22%. The article by Mao and 
colleagues presented in this issue is a meaningful contribution to 
our understanding of reversal as it examines the largest retrospective 
cohort to date.5 Interestingly, they report the rate of reversal as 
5% (95% CI: 3%–8%) in this Chinese cohort. It is difficult to reconcile 
the discrepancies in rates of reversibility and direct comparisons are 
hampered by the variable definitions employed. Using a novel definition 
for reversal (i.e, either endogenous testosterone (T) >270 ng dl−1, serum 
T gradually increasing above 150  ng dl−1 with increased testicular 
volume, or normal spontaneous sperm production/normal erectile 
function/ejaculation), Mao and colleagues posit that testicular size 
and triptorelin-stimulated LH levels are reliable predictive factors for 
reversal. However, these cannot be considered as hard and fast rules for 
predicting reversal as the groups intersect - akin to the overlap observed 
between CHH patients and those with delayed puberty. Indeed, the 
fact that approximately half (44%, 95% CI: 25%–66%) of the reversal 
patients in the study by Mao et al.5 were diagnosed between 17 and 
19 years of age, underscores the challenge in differentiating CHH from 
extreme normal variants of puberty.
This study further lends credence the recently reported 
observations that reversals may relapse.4,6 The notion that reversal 
may not be lasting highlights the vulnerability of the reproductive 
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axis among CHH patients. While the mechanism(s)  for relapse are 
unclear, it seems plausible that environmental, metabolic or psychiatric 
stressors could contribute. The factors that Mao and colleagues identify 
as significantly different in cases of reversal, were not informative for 
identifying those cases that relapsed back to a hypogonadal state. 
Notably, reversal has been reported in probands harboring mutations 
in genes underlying CHH.1,3,4,6 Unfortunately, comprehensive genetic 
screening on the Chinese cohort is not available.
The reversal phenomenon is fascinating for its glimpse into the 
plasticity of the neuroendocrine control of reproduction. Future 
directions will almost certainly include investigation of specific genetic 
signatures and novel biomarkers for predicting reversal (and relapse). 
Yet CHH is a rare condition and to fully elucidate the biology of 
reversible CHH, it will be important to harmonize definitions of what 
constitutes a reversal, carefully phenotype patients and chart the natural 
history of their CHH. In this way, this unique human disease model 
may offer further insights into the control of human reproduction 
and provide opportunities to translate discoveries into enhanced 
approaches to improve the care and quality of life for these patients.
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